Nothing Special   »   [go: up one dir, main page]

EA202193029A1 - Модулирование эффекторных функций антител - Google Patents

Модулирование эффекторных функций антител

Info

Publication number
EA202193029A1
EA202193029A1 EA202193029A EA202193029A EA202193029A1 EA 202193029 A1 EA202193029 A1 EA 202193029A1 EA 202193029 A EA202193029 A EA 202193029A EA 202193029 A EA202193029 A EA 202193029A EA 202193029 A1 EA202193029 A1 EA 202193029A1
Authority
EA
Eurasian Patent Office
Prior art keywords
panitumumab
site
molecules
contain
glycan
Prior art date
Application number
EA202193029A
Other languages
English (en)
Inventor
Скотт Томас Кунс
Рупа Падаки
Цинчунь ЧЖАН
Уилльям С. Бретцлафф
Original Assignee
Эмджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмджен Инк. filed Critical Эмджен Инк.
Publication of EA202193029A1 publication Critical patent/EA202193029A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

В данном документе представлены способы модулирования опосредованной рецептором Fc-гамма (FcR) цитотоксичности композиции на основе антитела. В иллюстративных вариантах осуществления способ предусматривает (1) увеличение или уменьшение количества концевой -галактозы в сайте гликозилирования N-297 панитумумаба или увеличение или уменьшение количества молекул панитумумаба, которые содержат галактозилированный гликан G1, G1a, G1b и/или G2 в сайте N-297, (2) увеличение или уменьшение количества молекул панитумумаба, которые содержат фукозилированный гликан в сайте N-297, или увеличение или уменьшение количества молекул панитумумаба, которые содержат афукозилированный гликан в сайте N-297, и (3) увеличение или уменьшение количества молекул панитумумаба, которые содержат гликан с высоким содержанием маннозы в сайте N-297.
EA202193029A 2019-05-06 2020-05-28 Модулирование эффекторных функций антител EA202193029A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962843919P 2019-05-06 2019-05-06
PCT/US2020/035016 WO2020227726A1 (en) 2019-05-06 2020-05-28 Modulating antibody effector functions

Publications (1)

Publication Number Publication Date
EA202193029A1 true EA202193029A1 (ru) 2022-03-17

Family

ID=71787041

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202193029A EA202193029A1 (ru) 2019-05-06 2020-05-28 Модулирование эффекторных функций антител

Country Status (14)

Country Link
US (1) US20220177580A1 (ru)
EP (1) EP3966246A1 (ru)
JP (1) JP2023530208A (ru)
KR (1) KR20230002024A (ru)
CN (1) CN114144434A (ru)
AU (1) AU2020268442A1 (ru)
BR (1) BR112021022202A2 (ru)
CA (1) CA3138584A1 (ru)
CL (1) CL2021002916A1 (ru)
EA (1) EA202193029A1 (ru)
IL (1) IL287551A (ru)
MX (1) MX2021013628A (ru)
SG (1) SG11202111992RA (ru)
WO (1) WO2020227726A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022192055A1 (en) * 2021-03-08 2022-09-15 Merck Sharp & Dohme Llc Reducing high mannose glycan protein expression using guanosine 5'-monophosphate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013114245A1 (en) 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition
WO2013114164A1 (en) 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Method for obtaining glycoprotein composition with increased afucosylation content
WO2013114167A1 (en) 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Process of obtaining glycoform composition
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
WO2015128793A1 (en) 2014-02-25 2015-09-03 Dr. Reddy’S Laboratories Limited A process for modifying high mannose and galactosylation content of a glycoprotein composition
WO2015140700A1 (en) 2014-03-19 2015-09-24 Dr. Reddy's Laboratories Limited Cell culture process
JP6698681B2 (ja) 2014-12-01 2020-05-27 アムジエン・インコーポレーテツド 糖タンパク質のグリカン含量のレベルを操作するためのプロセス
WO2017079165A1 (en) 2015-11-02 2017-05-11 Genentech, Inc. Methods of making fucosylated and afucosylated forms of a protein
WO2017134667A1 (en) 2016-02-02 2017-08-10 Insight Biopharmaceuticals Ltd. Methods of generating antibodies

Also Published As

Publication number Publication date
CN114144434A (zh) 2022-03-04
MX2021013628A (es) 2022-03-07
SG11202111992RA (en) 2021-11-29
BR112021022202A2 (pt) 2021-12-28
US20220177580A1 (en) 2022-06-09
IL287551A (en) 2021-12-01
EP3966246A1 (en) 2022-03-16
CA3138584A1 (en) 2020-11-12
AU2020268442A1 (en) 2021-11-25
WO2020227726A1 (en) 2020-11-12
KR20230002024A (ko) 2023-01-05
CL2021002916A1 (es) 2022-07-22
JP2023530208A (ja) 2023-07-14

Similar Documents

Publication Publication Date Title
AU2018272852A8 (en) Antibodies comprising modified heavy constant regions
AR072897A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
WO2020139920A3 (en) Activatable masked anti-ctla4 binding proteins
WO2008079995A3 (en) Conjugate of natriuretic peptide and antibody constant region
CY1112862T1 (el) Θραυσματα μονοσθενους αντισωματος χρησιμα ως θεραπευτικα
GEP20104887B (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
WO2016081746A8 (en) Antibodies comprising modified heavy constant regions
WO2004067568A3 (en) Human il-1 beta antagonists
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
MX2020008736A (es) Formulaciones de anticuerpos b7-h4.
WO2022082073A3 (en) Compositions and methods for muc18 targeting
WO2021212049A3 (en) Anti-sars-cov-2 monoclonal antibodies
MX2021015880A (es) Fragmentos de unión al antígeno cd3 y composiciones que comprenden los mismos.
MX2021005048A (es) Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
MX2022011958A (es) Conjugados de anticuerpo degradador y métodos de uso de los mismos.
EA202193029A1 (ru) Модулирование эффекторных функций антител
MX2021002750A (es) Anticuerpos anti-tnfrsf9 y usos de los mismos.
MX2021000688A (es) Anticuerpos anti-cd40 y usos de los mismos.
WO2006012621A3 (en) Compositions and methods for regulating the alternative pathway of complement
PH12020500662A1 (en) Anti-pfrh5 antibodies and antigen-binding fragments thereof
MX2023015028A (es) Nuevos aglutinantes del p2x7 disfuncional.
BR112023023284A2 (pt) Anticorpos para tratamento de alfa-sinucleinopatias
MX2022007513A (es) Anticuerpos biespecificos con cisteinas intercatenarias apareadas alternativamente y sus usos.
MX2022002672A (es) Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo.
WO2020127354A3 (en) Polypeptides